Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important.
Fatima LaherTaibat SalamiStefanie HornschuhLerato M MakhaleMamakiri KhunwaneMichele P AndrasikGlenda E GrayHong Van TieuJanan J DietrichPublished in: BMC public health (2020)
The participants' candour about barriers to condom and daily oral pre-exposure prophylaxis (PrEP) use, and expressed preferences for long-lasting, discreet, lifestyle-friendly methods reveal a gap in the biomedical prevention market aiming to reduce sexually acquired HIV in South Africa. Product developers should consider long-acting injectable formulations, such as vaccines, passive antibodies and chemoprophylaxis, for HIV prevention technologies. Future innovations in HIV prevention products may need to address the desire for the method to blend easily into lifestyles, such as food-medication formulations.
Keyphrases
- south africa
- hiv positive
- men who have sex with men
- hiv testing
- physical activity
- antiretroviral therapy
- hiv infected
- metabolic syndrome
- study protocol
- hepatitis c virus
- cardiovascular disease
- healthcare
- hiv aids
- weight loss
- phase iii
- current status
- genome wide
- type diabetes
- single cell
- phase ii
- hyaluronic acid
- human health
- risk assessment
- gene expression
- emergency department
- low cost
- dna methylation